The integration of docetaxel into first-line chemotherapy for ovarian cancer
- 1 July 2001
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 11 (s1) , 31-33
- https://doi.org/10.1046/j.1525-1438.2001.11(suppl.1)sup1031.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerBritish Journal of Cancer, 2001
- Docetaxel for Patients With Paclitaxel-Resistant Müllerian CarcinomaJournal of Clinical Oncology, 2000
- The impact of specialist training for surgery in ovarian cancerInternational Journal of Gynecologic Cancer, 2000
- Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian CancerJournal of Clinical Oncology, 1999
- A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancerOncogene, 1999
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995